APC Advanced Proteome Therapeutics Corporation

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (FSE:0E8) is pleased to announce the appointments of two new members to its Scientific Advisory Board (SAB):  Dr. Aditya Bardia, a board-certified medical oncologist, is an Attending Physician at Massachusetts General Hospital Cancer Center (MGHCC), Harvard Medical School, Boston, and Dr. Greg Thurber, is a member of the Faculty of Chemical Engineering and Biomedical Engineering at the University of Michigan.

Dr. Bardia, who is Director of the Precision Oncology Program at the MGH Center for Breast Cancer, is active in areas which span the integration of precision diagnostics and precision therapeutics for significantly improving the outcomes of patients afflicted with breast cancer, to research in the evolving field of liquid biopsy for early cancer detection. He has been the principal investigator of several clinical trials related to novel therapies in breast cancer, including antibody-drug conjugates such as sacituzumab govitecan (IMMU-132) that was given breakthrough designation status by the FDA in 2016. Dr. Bardia has been the recipient of numerous awards as well as being co-leader of the Molecular and Precision tumor board at MGHCC, and an editorial board member of the American Society of Clinical Oncology (ASCO), Tumor Board. Dr. Thurber’s work involves applying fundamental biotransport principles to design novel therapeutics and molecular imaging agents and developing an understanding of the critical factors that govern the distribution of agents, such as antibody-drug conjugates, in cells and tissues, to optimize their efficacies. An important point of focus is the matter of compatibility among antibody, linker, and toxin that comprise an ADC, which is central to the clinical success of this agent. Dr. Thurber, who has been a member of the Junior Faculty, Harvard Medical School/Massachusetts General Hospital, in the Radiology Department, has received several awards and is the recipient of a National Science Foundation CAREER award.

Dr. Allen Krantz, the founder of APC, commented, “We are extremely fortunate to have Drs. Bardia and Thurber serve as members of the SAB in this phase of the Company’s development. Having their formidable knowledge and expertise bearing on the field of antibody-drug conjugates will certainly be an asset for us in the challenges that lie ahead and are well-aligned with our objectives.”

“Many thanks are also due to Drs. Stephen Hanessian, Isis Pharmaceuticals Research Chair in Medicinal Chemistry at the Universite de Montreal and Steven Withers, Canada Research Chair in Chemical Biology at the University of British Columbia for serving on the SAB since the inception of the Company and making available their capabilities in the design and discovery of novel therapeutics.”

ABOUT THE COMPANY:

Advanced Proteome Therapeutics Corporation is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells.  This type of agent is capable of greater potency, higher specificity and lower toxicity than other therapies that can also attack healthy cells.  The Company is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential.

FOR FURTHER INFORMATION PLEASE CONTACT:

Advanced Proteome Therapeutics Corporation Dr. Allen Krantz COO and CSO Tel: 617 638 0340 http://www.advancedproteome.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.